Blood & blood forming organs
EU DMF readiness
US DMF readiness
Rivaroxaban belongs to the class of antithrombotic agents. Rivaroxaban reduces a risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack. It is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
It is formulated as film-coated tablet and tablet for oral administration.
Mechanism of action:
Rivaroxaban is a factor Xa inhibitor. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombus. By blocking factor Xa, the level of thrombin decreases, which reduces the risk of blood clots forming in the veins and arteries, and also treats existing clots.
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.